Company Mydecine Innovations Group Inc. NEO Exchange
Equities
MYCO
CA62849F2008
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.175 CAD | +45.83% | +29.63% | -61.11% |
05-01 | Mydecine Innovations Group Inc. announced that it expects to receive CAD 1 million in funding | CI |
02-23 | Mydecine Innovations Closes Partial Debt Settlement | MT |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Robert Roscow
FOU | Founder | - | 26/09/13 |
Damon Michaels
FOU | Founder | - | 26/09/13 |
David Bartch
CEO | Chief Executive Officer | - | 21/06/18 |
John Ross
DFI | Director of Finance/CFO | 65 | 15/09/22 |
Sanford Stein
CMP | Compliance Officer | - | 31/12/19 |
Rakesh Jetly
CTO | Chief Tech/Sci/R&D Officer | 57 | 16/11/20 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
David Bartch
CEO | Chief Executive Officer | - | 21/06/18 |
Damon Michaels
FOU | Founder | - | 26/09/13 |
Robert Roscow
FOU | Founder | - | 26/09/13 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 61,755,385 | 61,161,194 ( 99.04 %) | 0 | 99.04 % |
Company contact information
Mydecine Innovations Group, Inc.
789 West Pender Street Suite 810
V6C 1H2, Vancouver
+720-277-9879
http://mydecine.comSector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+50.47% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
-1.62% | 11.98B |
- Stock Market
- Equities
- MYCOF Stock
- MYCO Stock
- Company Mydecine Innovations Group Inc.